Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
91 hedge funds and large institutions have $213M invested in Surface Oncology, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 10 closing their positions.
320% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 10
54% more funds holding
Funds holding: 59 → 91 (+32)
44% more capital invested
Capital invested by funds: $149M → $213M (+$64.8M)
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
41% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $2.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$18.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.69M |
| 3 |
Morgan Stanley
New York
|
+$8.57M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.97M |
| 5 |
BlackRock
New York
|
+$5.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$28.5M |
| 2 |
VA
VR Adviser
New York
|
-$21.2M |
| 3 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$14.8M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$12.1M |
| 5 |
Renaissance Technologies
New York
|
-$2.63M |
SURF Hedge Fund Activity: Q4 2020 in Review
91 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2020, worth a combined $213M — up 44% from $149M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new SURF positions and 10 closed out — a net gain of 32 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $18.2M. The largest seller was EcoR1 Capital, cutting an estimated $28.5M.
- 91 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2020, up from 59 in Q3 2020.
- Funds reported $213M of Surface Oncology, Inc. Common Stock stock for Q4 2020, up 44% quarter-over-quarter.
- 42 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +32 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q4 2020 was ARK Investment Management, an estimated $18.2M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q4 2020 was EcoR1 Capital, an estimated $28.5M sold.
Based on aggregated 13F filings for Q4 2020.